Purpose {#sec1}
=======

External beam radiotherapy (EBRT), concomitant chemotherapy, and brachytherapy is the modern treatment modality for advanced cervical cancer. Brachytherapy is an integral part of radiation treatment of cervical cancer. Studies have shown a clear dose-volume effect between modern dosimetric parameters (D~90~ of high-risk clinical target volume \[HR-CTV\] and intermediate-risk clinical target volume \[IR-CTV\]) and the probability of achieving local control \[[@cit0001],[@cit0002]\]. For cervical cancer brachytherapy, common standardized applicators include tandem and ring applicators, tandem and ovoid applicators, vaginal cylinders, combined intracavitary and interstitial (IC/IS) applicators, and the Martinez universal perineal interstitial template \[[@cit0003],[@cit0004],[@cit0005],[@cit0006]\]. Each applicator has its own unique structural characteristics and is applicable to a specific situation.

For special tumor morphology and topography, brachytherapy cannot achieve a good absorbed-dose coverage of the target volume for using standardized applicators due to a steep dose gradient, thereby not achieving good local control. Many studies have made many attempts in the field of individualized applicators and have achieved good results \[[@cit0007],[@cit0008],[@cit0009],[@cit0010]\]. The aim of this pictorial essay is to demonstrate the workflow of an individualized cylindrical vaginal applicator with oblique guide holes using 3D modeling and printing technologies.

Material and methods {#sec2}
====================

A 47-year-old woman was diagnosed with stage IIIA cervical cancer after having a subtotal hysterectomy for uterine fibroids 10 years prior. A gynecological examination and magnetic resonance imaging (MRI) showed that the tumor was located at the anterior lip of the cervix, the upper one-third of the anterior wall of the vagina, and the left one-third of the parauterine organ, with a size of 5.6 **×** 3 **×** 3.8 cm^3^. The dose of EBRT was 45 Gy/25 fractions delivered by intensity-modulated radiation therapy. After EBRT, a gynecological examination showed that the tumor involved the upper one-third of the anterior vaginal wall with a 2 cm maximum extension in depth. In consideration of her stenotic vagina and tumor location, we applied the individualized vaginal cylinder applicator with guide holes. The design of the applicator was based on the preplanning steps: computed tomography (CT) simulation and contour ([Figure 1](#f0001){ref-type="fig"}), establishment of coordinate system of the applicator ([Figure 2](#f0002){ref-type="fig"}), optimized design of needle path ([Figures 3](#f0003){ref-type="fig"}-[5](#f0005){ref-type="fig"}), and dose distribution optimization ([Figure 6](#f0006){ref-type="fig"}). The delineation of the target volumes was contoured according to recommendations from the GYN GEC-ESTRO Working Group \[[@cit0011]\]. Data on the direction for the needles based on the coordinate system are shown in [Table 1](#t0001){ref-type="table"}. According to the data from the preplanning phase, the 3D modeling of the applicator ([Figures 7](#f0007){ref-type="fig"}-[10](#f0010){ref-type="fig"}) was implemented in 3ds Max (2015 version, Autodesk Inc., San Rafael, CA, USA). The 3D printing process of the applicator is shown in [Figures 11](#f0011){ref-type="fig"}-[13](#f0013){ref-type="fig"}. The implantation of the applicator and the needles was performed under the guidance of transrectal ultrasound in every application. We used the following brachytherapy treatment schema: 4 fractions, 7 Gy/fraction; 1 week apart for total treatment time of 57 days (including EBRT).

###### 

The coordinate data for two points of each implant needle (cm)

  Needle umber   Base end   Tip end                         
  -------------- ---------- --------- ------- ------- ----- -----
  1              --1.0      0.0       0.1     --1.0   6.0   0.1
  2              --0.6      0.0       1.0     --0.6   6.0   1.0
  3              0.0        0.0       0.3     0.0     7.0   2.7
  4              0.0        0.0       --0.3   0.0     7.0   1.8
  5              0.0        0.0       --1.0   0.0     7.0   0.1
  6              0.6        0.0       1.0     0.6     6.0   1.0
  7              1.0        0.0       0.1     1.0     6.0   0.1
  8              0.0        0.0       1.0     0.5     3.3   1.5

![I. Preplanning: CT simulation was performed after a vaginal model (a half sphere 3 cm in diameter and a cylinder 6 cm in length and 3 cm in diameter) was implanted into the vagina. The target volumes were delineated on reconstructed CT images with reference MR images before implantation. The red dotted line is the HR-CTV, and the green dotted line is the IR-CTV: **A**) para-axial plane (according to dummy applicator), **B**) sagittal plane, **C**) para-coronal plane (according to dummy applicator), **D**) 3D view](JCB-11-37894-g001){#f0001}

![I. Preplanning: To design convenient directions of the implanted needles, we established the coordinate system of the applicator as follows: the x-axis is the left and right direction, where the left of the patient is positive; the z-axis is the anterior and posterior direction, where the anterior of the patient is positive; the y-axis is the head and foot direction, and the head of the patient is positive. We designed an ideal implanted needle according to the relationship between the tumor (red coil) and the vaginal cylinder (blue) while considering the needle distribution. Two points determine a straight line (the implant needle). The superior point is called the "tip end", and the inferior point is called the "base end"](JCB-11-37894-g002){#f0002}

![I. Preplanning: The needle directions parallel to the axis of the applicator: **A**) the transverse section with labels for the other subgraphs: **B**) the first, **C**) the second, **D**) the third to the fifth, **E**) the sixth, and **F**) the seventh needles](JCB-11-37894-g003){#f0003}

![I. Preplanning: To obtain better target coverage, we set an oblique needle, which was both forward and left with respect to the patient: **A**) para-axial plane (according to needle No. 8), **B**) para-sagittal plane (according to needle No. 8), **C**) para-coronal plane (according to needle No. 8), **D**) 3D view](JCB-11-37894-g004){#f0004}

![I. Preplanning: We obtained the directional data of the needles, which are shown in [Table 1](#t0001){ref-type="table"}, according to the relationship between the needles and the coordinate system: **A**) base end of applicator, **B**) 3.3 cm upper from the base end of applicator](JCB-11-37894-g005){#f0005}

![I. Preplanning: The relationship between the preplanned isodose curves and the target volume: **A**) para-axial plane (according to applicator), **B**) sagittal plane, **C**) para-coronal plane (according to applicator), **D**) 3D view](JCB-11-37894-g006){#f0006}

![II. 3D modeling: Modeling of the main body of the vaginal applicator without guide holes: the Boolean union of a cylinder and a sphere](JCB-11-37894-g007){#f0007}

![II. 3D modeling: The needles were constructed as cylinders (shown within the main body of the vaginal applicator), and the distribution and direction were adjusted according to the data shown in [Table 1](#t0001){ref-type="table"}](JCB-11-37894-g008){#f0008}

![II. 3D modeling: A cylindrical applicator with oblique guide holes was obtained using Boolean subtraction](JCB-11-37894-g009){#f0009}

![II. 3D modeling: A mark (red arrow) was included on the main body of the applicator, which just pointed to the anterior of the patient; the Foley catheter passed through this mark](JCB-11-37894-g010){#f0010}

![III. 3D printing: The modeling data were exported as an "\*.stl" file to MakerBot Print (version 3.0, MakerBot Industries, USA). In MakerBot Print, the file was processed and exported as a "\*. makerbot" file to the 3D printer](JCB-11-37894-g011){#f0011}

![III. 3D printing: The model was printed using a 3D printer (Replicator +, MakerBot USA) with polylactic acid (PLA) material](JCB-11-37894-g012){#f0012}

![III. 3D printing: The 3D graphics in the preplanning phase (**A**) and the cylindrical applicator with oblique needles after 3D printing (**B**) were compared](JCB-11-37894-g013){#f0013}

Results {#sec3}
=======

An example (the first fraction) of the relationship between the isodose curves and the target volumes or organs at risk (OARs) is shown in [Figure 14](#f0014){ref-type="fig"}. The DVH parameters for all the treatment plans, including the preplanning phase, are shown in [Table 2](#t0002){ref-type="table"}. Brachytherapy was well tolerated and achieved a satisfactory total equivalent dose in 2 Gy/fraction (EQD~2~) for HR-CTV. At the last follow-up at 24 months after brachytherapy, there was no evidence of recurrence in the pelvic region and no signs or symptoms of complications (see [Figure 15](#f0015){ref-type="fig"}).

###### 

Dose parameters of target volumes and OARs (cGy)

  Parameter          Preplanning   BT1    BT2    BT3    BT4    Total[\*](#tf2-1){ref-type="table-fn"}   Planning aims[\*\*](#tf2-2){ref-type="table-fn"}   Limits dose[\*\*](#tf2-2){ref-type="table-fn"}
  ------------------ ------------- ------ ------ ------ ------ ---------------------------------------- -------------------------------------------------- ------------------------------------------------
  HR-CTV D~98~       588           618    660    548    591    7662                                     \> 7500                                            --
  HR-CTV D~90~       714           724    756    732    732    8684                                     \> 9000                                            \> 8500
  HR-CTV D~50~       1177          1157   1112   1200   1173   12786                                    --                                                 --
  IR-CTV D~98~       415           415    501    318    387    6338                                     \> 6000                                            --
  Bladder D~0.1cc~   659           691    638    570    539    8783                                     --                                                 --
  Bladder D~2cc~     571           531    550    474    443    7530                                     \< 8000                                            \< 9000
  Rectum D~0.1cc~    493           445    544    542    383    7337                                     --                                                 --
  Rectum D~2cc~      383           361    403    381    294    6232                                     \< 6500                                            \< 7500
  Sigmoid D~0.1cc~   677           633    392    617    557    8130                                     --                                                 --
  Sigmoid D~2cc~     490           467    292    436    417    6622                                     \< 7000                                            \< 7500
  Bowel D~2cc~       459           480    446    413    471    7049                                     \< 7000                                            \< 7500

Total dose was EQD~2~, which is the dose using a linear-quadratic (LQ) equation with α/β = 10 for a tumor and α/β = 3 for OARs, including 45 Gy/25 f EBRT.

Objective recommendation from EMBRACE II

![IV. Treatment plan: An example (the first fraction) of the relationship between the isodose curves and the target volumes or OARs: **A**) para-axial plane (according to applicator), **B**) sagittal plane, **C**) para-coronal plane (according to applicator), **D**) 3D view](JCB-11-37894-g014){#f0014}

![IV. Clinical outcome: MRI showed no evidence of recurrence in the pelvic region at **A**) 9 months, **B**) 12 months, **C**) 16 months, and **D**) 24 months after brachytherapy](JCB-11-37894-g015){#f0015}

Discussion {#sec4}
==========

In conventional 2D brachytherapy, individualized treatment cannot be achieved. The use of 3D brachytherapy shows a trend towards increased local control and improved overall survival with reduced toxicity compared to 2D brachytherapy \[[@cit0012]\]. At present, individualized treatment is a recommended strategy for cervical cancer brachytherapy in the modern management of cervical cancer \[[@cit0008],[@cit0013]\]. This paper introduced the design and application of an individualized cylindrical vaginal applicator using 3D modeling and printing technologies and achieved good clinical results. This paper introduces only the production process of the individualized vaginal cylindrical applicators. The specific 3D modeling software and 3D printer used in this study are replaceable. As long as other software and hardware have the corresponding functions, they can be used to replace the software and hardware introduced in this paper. In the preplanning phase, the delineation of target volumes and OARs is not directly based on MRI but on CT images cross-referenced with an MRI image. Although this method is not the best strategy, it is an acceptable secondary option to some extent. Readers can follow the workflow of this study and perform the preplanning phase based on MRI, which will bring more optimized results. In this study, the design of an individualized cylindrical vaginal applicator was based on the data acquired in the preplanning phase, which is an effective method, and preplanning is also recommended in all brachytherapy plans \[[@cit0014]\].

Four fractions of brachytherapy achieved the ideal dose distribution. [Figure 6](#f0006){ref-type="fig"} shows that the isodose line of the prescribed dose covered the HR-CTV well and avoided OARs well. From [Table 2](#t0002){ref-type="table"}, it can be seen that the total EQD~2~ of the target volumes and the OARs all achieved the limit dose, and 5 of the 7 items achieved the planning aim dose. This result fully shows that the individualized cylindrical vaginal applicator using 3D modeling and printing technologies has good availability, practicability and repeatability.

For cervical cancer brachytherapy after subtotal hysterectomy, cylindrical vaginal applicators are commonly used applicators. Because of the high dose gradient in brachytherapy, when the depth of vaginal infiltration is far greater than 5 mm, it is impossible to achieve both a high dose coverage of the prescribed dose for the target volumes and a low dose to OARs \[[@cit0006]\]. The individualized applicator introduced in this paper can be used for deep vaginal invasion, vaginal tumors with asymmetric growth, vaginal recurrences, and vaginal cuff recurrence after subtotal hysterectomy.

Conclusions {#sec5}
===========

When standardized applicators cannot achieve a good dose distribution for cervical cancer after subtotal hysterectomy, one can achieve a higher dose coverage of the target and better sparing of the OARs by using a 3D-printed, individualized cylindrical vaginal applicator.
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